1-8 of 8
Wojciech Jurczak
Close
Sort by
Journal Articles

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials

Clinical Trials & Observations
Matthew S. Davids, Jeff P. Sharman, Paolo Ghia, Jennifer A. Woyach, Toby A. Eyre, Wojciech Jurczak, Tanya Siddiqi, Paulo Miranda, Mina Shahkarami, Anna Butturini, Ugochinyere Emeribe, John C. Byrd
Journal: Blood Advances
Blood Adv (2024) 8 (13): 3345–3359.
https://doi.org/10.1182/bloodadvances.2023011307
Published: 2024
Includes: Supplemental data
Journal Articles

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis

Clinical Trials & Observations
Michael L Wang, Tadeusz Robak, Prof., Kami J Maddocks, Tycel J. Phillips, Stephen Douglas Smith, David Gallinson, Roser Calvo, MD PhD, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak
Journal: Blood Advances
Blood Adv bloodadvances.2023012424.
https://doi.org/10.1182/bloodadvances.2023012424
Published: 2024
Includes: Supplemental data
Journal Articles

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia

Clinical Trials & Observations
Constantine S. Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García-Sanz, Helen McCarthy, Stephen Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jarosław Czyż, Carlos Fernández De Larrea, David Belada, Edward Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C. Minnema, Christian Buske, Véronique Leblond, Steven P. Treon, Judith Trotman, Binghao Wu, Yiling Yu, Zhirong Shen, Wai Y. Chan, Jingjing Schneider, Heather Allewelt, Aileen Cohen, Meletios A. Dimopoulos
Journal: Blood Advances
Blood Adv (2024) 8 (7): 1639–1650.
https://doi.org/10.1182/bloodadvances.2023010906
Published: 2024
Includes: Supplemental data
Journal Articles

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Clinical Trials & Observations
Tycel J. Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Ping Jiang, Peter Johnson
Journal: Blood Advances
Blood Adv (2024) 8 (4): 867–877.
https://doi.org/10.1182/bloodadvances.2023010648
Published: 2024
Includes: Supplemental data
Journal Articles

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies

Clinical Trials & Observations
Constantine S. Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, Judith Trotman, Stephen Opat, Andrew W. Roberts, Roger Owen, Yuqin Song, Wei Xu, Jun Zhu, Jianyong Li, Lugui Qiu, Shirley D’Sa, Wojciech Jurczak, Gavin Cull, Paula Marlton, David Gottlieb, Javier Munoz, Tycel Phillips, Chenmu Du, Meng Ji, Lei Zhou, Haiyi Guo, Hongjie Zhu, Wai Y. Chan, Aileen Cohen, William Novotny, Jane Huang, Alessandra Tedeschi
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1296–1308.
https://doi.org/10.1182/bloodadvances.2021005621
Published: 2022
Includes: Supplemental data
Journal Articles

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Clinical Trials & Observations
Matthew S. Davids, Owen A. O’Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske, Pier Luigi Zinzani, Manish R. Patel, Nilanjan Ghosh, Bruce D. Cheson, Enrico Derenzini, Danielle M. Brander, James A. Reeves, Wanda Knopińska-Posłuszny, John N. Allan, Tycel Phillips, Paolo F. Caimi, Ewa Lech-Maranda, John M. Burke, Richy Agajanian, Ruth Pettengell, Lori A. Leslie, Chan Y. Cheah, Gustavo Fonseca, James Essell, Julio C. Chavez, John M. Pagel, Jeff P. Sharman, Yanzhi Hsu, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Ian W. Flinn
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5332–5343.
https://doi.org/10.1182/bloodadvances.2021005132
Published: 2021
Includes: Supplemental data
Journal Articles

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study

Clinical Trials & Observations
Christian Buske, Wojciech Jurczak, Juan-Manuel Sancho, Edvard Zhavrid, Jin Seok Kim, José-Ángel Hernández-Rivas, Aliaksandr Prokharau, Mariana Vasilica, Rajnish Nagarkar, Larry Kwak, Won-Seog Kim, SangJoon Lee, SungHyun Kim, KeumYoung Ahn, Michinori Ogura
Journal: Blood Advances
Blood Adv (2021) 5 (17): 3354–3361.
https://doi.org/10.1182/bloodadvances.2021004484
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 1/2a study of 177 Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Clinical Trials & Observations
Arne Kolstad, Tim Illidge, Nils Bolstad, Signe Spetalen, Ulf Madsbu, Caroline Stokke, Johan Blakkisrud, Ayca Løndalen, Noelle O'Rourke, Matthew Beasley, Wojciech Jurczak, Unn-Merete Fagerli, Michal Kaščák, Mike Bayne, Aleš Obr, Jostein Dahle, Lisa Rojkjaer, Veronique Pascal, Harald Holte
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4091–4101.
https://doi.org/10.1182/bloodadvances.2020002583
Published: 2020
Includes: Supplemental data